Niagen Bioscience Inc (NAGE)

$9.61 +0.21 (2.23%)
Market Cap 740.44M
Revenue (ttm) 99.60M
Net Income (ttm) 8.55M
EPS (ttm) N/A
PE Ratio 101.78
Forward PE 72.32
Profit Margin 8.58%
Debt to Equity Ratio 0.00
Volume 3,098,800
Avg Vol 1,148,676
Day's Range N/A - N/A
Shares Out 78.77M
Stochastic %K 33%
Beta 2.12
Analysts Strong Sell
Price Target $14.90

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
tymtested
tymtested Aug. 8 at 12:30 AM
$NAGE increasing demand for NR will trump all manipulation games. Just buy and hold.
0 · Reply
tymtested
tymtested Aug. 8 at 12:28 AM
$NAGE there are people who know the results of the trials… patients families, people involved in data collection etc. they will be quietly buying.
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Aug. 7 at 10:36 PM
$NAGE Would love to see a 15% price reduction for the capsules.
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 10:18 PM
$NAGE Rob Fried said yesterday that they do not know the results of the No Park trial. We should receive a big hint though before the results are released if we see Niagen Bio taking preliminary steps to take advantage of the results. In some ways we may have seen that already. Although the company does not yet know the complete results, they likely know whether some participants showed improved symptoms during the trials, even without knowing which participants got NR and when. Since people do not spontaneously improve with Parkinsons' disease, it would be an easy leap to conclude that those who got NR were the ones whose conditions got better. We have already seen that they started a subsidiary company, wholly owned by Niagen Bio, to handle the pharmaceutical uses of Niagen., and their enthusiasm about the trials is obvious.
1 · Reply
Obrady
Obrady Aug. 7 at 9:42 PM
$NAGE always manipulated. What a joke!
0 · Reply
Rhinoman67
Rhinoman67 Aug. 7 at 8:46 PM
$NAGE One way to affect the people shorting the stock is to make your shares unavailable for your broker to “borrow” your shares and make them available for short sellers. Call your broker and tell them to make your shares unavailable. They will give you any steps necessary. This makes less shares available to short which will increase the borrowing cost for shorting the stock, making it less appealing.
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 8:11 PM
$NAGE - This is my math regarding the No Park trials using the 3000 mg dose in the EU alone, based on there being 1.2 million people in the EU with Parkinson's disesse and most countries in the EU providing health care and necessary drug treatments, and only half of the PD victims getting Niagen for some reason: 600,000 victims x 12 months x $100 profit to Niagen Bio = $720 million divided by 80 million shares = $9.00 per share profit x 15 PE ratio = $135 SP based on Parkinson's disease in the EU alone.
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 7:54 PM
$NAGE - How about crusie ship IV/injections and selling Niagen capsules? Cruise ships have an older clientele with money, time on their hands on the ship, easy access with the in-room TVs and daily news letters, the option of seminars onboard, and medical staff that mainly have nothing to do all day.
1 · Reply
stupidusername
stupidusername Aug. 7 at 6:32 PM
$NAGE happy for $CCCC but $NAGE had amazing earnings and nothing. Why the difference?
1 · Reply
wycliff
wycliff Aug. 7 at 4:10 PM
$NAGE https://www.investing.com/news/transcripts/earnings-call-transcript-niagen-bioscience-q2-2025-earnings-beat-expectations-93CH-4175185
1 · Reply
Latest News on NAGE
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Aug 6, 2025, 4:02 PM EDT - 1 day ago

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:32 AM EDT - 3 days ago

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 23, 2025, 8:34 AM EDT - 15 days ago

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Jul 14, 2025, 8:32 AM EDT - 24 days ago

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Jul 8, 2025, 8:32 AM EDT - 4 weeks ago

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Jun 24, 2025, 4:27 PM EDT - 6 weeks ago

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Jun 20, 2025, 8:32 AM EDT - 6 weeks ago

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Niagen Bioscience to Participate in the BIO 2025 International Convention

Jun 11, 2025, 8:31 AM EDT - 2 months ago

Niagen Bioscience to Participate in the BIO 2025 International Convention

Niagen Bioscience: High Conviction, High Expectations

Jun 11, 2025, 6:48 AM EDT - 2 months ago

Niagen Bioscience: High Conviction, High Expectations

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Jun 9, 2025, 8:32 AM EDT - 2 months ago

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Jun 4, 2025, 8:32 AM EDT - 2 months ago

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

May 10, 2025, 1:40 PM EDT - 3 months ago

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 7, 2025, 4:02 PM EDT - 3 months ago

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 5, 2025, 8:32 AM EDT - 3 months ago

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Apr 29, 2025, 8:32 AM EDT - 3 months ago

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 28, 2025, 8:34 AM EDT - 3 months ago

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Apr 7, 2025, 10:32 PM EDT - 4 months ago

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Apr 7, 2025, 8:32 AM EDT - 4 months ago

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

Mar 20, 2025, 8:34 AM EDT - 5 months ago

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Mar 19, 2025, 8:34 AM EDT - 5 months ago

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

Mar 13, 2025, 8:34 AM EDT - 5 months ago

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 5 months ago

ChromaDex to Present at the 37th Annual Roth Conference

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

Mar 6, 2025, 10:30 AM EST - 5 months ago

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 8:53 PM EST - 5 months ago

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Mar 4, 2025, 4:02 PM EST - 5 months ago

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 25, 2025, 4:07 PM EST - 5 months ago

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 6, 2025, 8:32 AM EST - 7 months ago

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

Dec 3, 2024, 8:34 AM EST - 8 months ago

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

Nov 14, 2024, 8:32 AM EST - 9 months ago

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

Nov 7, 2024, 8:32 AM EST - 9 months ago

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 2:48 PM EDT - 9 months ago

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 4:04 PM EDT - 10 months ago

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Oct 28, 2024, 8:32 AM EDT - 10 months ago

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Oct 23, 2024, 8:34 AM EDT - 10 months ago

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

Oct 15, 2024, 8:32 AM EDT - 10 months ago

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

Sep 26, 2024, 4:12 PM EDT - 11 months ago

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

Sep 20, 2024, 8:32 AM EDT - 11 months ago

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

Sep 10, 2024, 8:32 AM EDT - 11 months ago

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

Sep 9, 2024, 8:34 AM EDT - 11 months ago

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

Aug 23, 2024, 8:34 AM EDT - 1 year ago

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

Aug 19, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:04 PM EDT - 1 year ago

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 5, 2024, 8:32 AM EDT - 1 year ago

ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Jul 24, 2024, 8:34 AM EDT - 1 year ago

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

Jul 23, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

Jul 22, 2024, 8:34 AM EDT - 1 year ago

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

Jul 16, 2024, 8:34 AM EDT - 1 year ago

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

ChromaDex to Join Russell 2000® Index

Jul 1, 2024, 8:32 AM EDT - 1 year ago

ChromaDex to Join Russell 2000® Index

ChromaDex: Looking To Take The Big Step Into Pharma

Jun 26, 2024, 12:20 PM EDT - 1 year ago

ChromaDex: Looking To Take The Big Step Into Pharma

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

Jun 24, 2024, 8:32 AM EDT - 1 year ago

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

tymtested
tymtested Aug. 8 at 12:30 AM
$NAGE increasing demand for NR will trump all manipulation games. Just buy and hold.
0 · Reply
tymtested
tymtested Aug. 8 at 12:28 AM
$NAGE there are people who know the results of the trials… patients families, people involved in data collection etc. they will be quietly buying.
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Aug. 7 at 10:36 PM
$NAGE Would love to see a 15% price reduction for the capsules.
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 10:18 PM
$NAGE Rob Fried said yesterday that they do not know the results of the No Park trial. We should receive a big hint though before the results are released if we see Niagen Bio taking preliminary steps to take advantage of the results. In some ways we may have seen that already. Although the company does not yet know the complete results, they likely know whether some participants showed improved symptoms during the trials, even without knowing which participants got NR and when. Since people do not spontaneously improve with Parkinsons' disease, it would be an easy leap to conclude that those who got NR were the ones whose conditions got better. We have already seen that they started a subsidiary company, wholly owned by Niagen Bio, to handle the pharmaceutical uses of Niagen., and their enthusiasm about the trials is obvious.
1 · Reply
Obrady
Obrady Aug. 7 at 9:42 PM
$NAGE always manipulated. What a joke!
0 · Reply
Rhinoman67
Rhinoman67 Aug. 7 at 8:46 PM
$NAGE One way to affect the people shorting the stock is to make your shares unavailable for your broker to “borrow” your shares and make them available for short sellers. Call your broker and tell them to make your shares unavailable. They will give you any steps necessary. This makes less shares available to short which will increase the borrowing cost for shorting the stock, making it less appealing.
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 8:11 PM
$NAGE - This is my math regarding the No Park trials using the 3000 mg dose in the EU alone, based on there being 1.2 million people in the EU with Parkinson's disesse and most countries in the EU providing health care and necessary drug treatments, and only half of the PD victims getting Niagen for some reason: 600,000 victims x 12 months x $100 profit to Niagen Bio = $720 million divided by 80 million shares = $9.00 per share profit x 15 PE ratio = $135 SP based on Parkinson's disease in the EU alone.
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 7:54 PM
$NAGE - How about crusie ship IV/injections and selling Niagen capsules? Cruise ships have an older clientele with money, time on their hands on the ship, easy access with the in-room TVs and daily news letters, the option of seminars onboard, and medical staff that mainly have nothing to do all day.
1 · Reply
stupidusername
stupidusername Aug. 7 at 6:32 PM
$NAGE happy for $CCCC but $NAGE had amazing earnings and nothing. Why the difference?
1 · Reply
wycliff
wycliff Aug. 7 at 4:10 PM
$NAGE https://www.investing.com/news/transcripts/earnings-call-transcript-niagen-bioscience-q2-2025-earnings-beat-expectations-93CH-4175185
1 · Reply
tuttiter
tuttiter Aug. 7 at 3:25 PM
$NAGE Have they tapped into med spas yet? They should if they haven't yet!
1 · Reply
wycliff
wycliff Aug. 7 at 3:05 PM
$NAGE https://u11022783.ct.sendgrid.net/ls/click?upn=u001.TY5v8o67YiN0b3eOgh-2Bofd7a-2Fbft3NOEtkMZKqI4TiS7Sy8i6ItfATlxIF6Z4IWEiN-2B3R0dxy4qDphlY1IIZRNu3PVpXJm5e-2FQm-2FJEDJ4b4oKqIaeMoLcY8W1-2BNqhPNrijhhZRNdqZsBkOOR6chwlQgkQqGolUasLUpV-2FJcnN3TCktTETrn1T8WFce-2FthYt0sSnI_yi-2FF8O9dI2IZIjwMOLdjRPz-2FbuGWjWoi1PmCLi4JX8FeCZ-2FDiYZltXM3qUuENtbaZGebZ3IEiz8ekysdat-2FfiUFdVATMLfhHkOfemNpdG-2BwvxEL9bj41RKMiCr1O4-2F5GKBKA0M1HpzX-2FKk-2BLEojTRmNDa-2B-2F5AbA-2BUYSdDJmXw8JWyBPblH-2FlR8hmmQI-2FmKhzFMjtuNJJJ5iww3EwNNzVz-2B4XGN9kHSZaVoVTVcHPF-2FgzYtC9Rbhf6qew7NkTuoSXnIkp9zeqlL1izFwPIHaiEzXcnV7Afcyqo3WTenUKgqVCiVzX6yUpfubGKeOdQuHNrXdBXJid9B0THpu4GHg1ZigZ30yw3ycYD4X-2BEFk3bIfgmYz1Kb2Wr-2BQGrdcb363p
0 · Reply
wycliff
wycliff Aug. 7 at 2:59 PM
$NAGE https://finance.yahoo.com/news/niagen-bioscience-present-canaccord-genuity-123200405.html
0 · Reply
Mikeqb20
Mikeqb20 Aug. 7 at 2:36 PM
$NAGE ADDED 7,500 Niagen MOFO's!!! Great numbers....great guidance moving forward @NiagenFan @ACInvestorBlog @topstockalerts @IncredibleTrade
0 · Reply
Want2makeAmillon
Want2makeAmillon Aug. 7 at 2:17 PM
$NAGE this should be up $2-4 dollars right now!
1 · Reply
stocksrream
stocksrream Aug. 7 at 2:11 PM
$XLV looks like $NAGE getting affected by a ALGO trade cause of $LLY
0 · Reply
stupidusername
stupidusername Aug. 7 at 1:45 PM
$NAGE crazy volume but not moving up. Doubtful this is all profit taking. Likely to reverse
1 · Reply
Baba200TradeBot
Baba200TradeBot Aug. 7 at 12:30 PM
LowFloatReport.com - ⬆️ - Top 5 Low Float Gap Up Stay Up (Premarket 2) as of 08/07/25 - 8:30 AM $CREG - Volume: 11.8M - Prev Volume: 0 - Float: 1.99 - Rel Vol: 420.7x - Chng%: +20.0% $CMCT - Volume: 10.0M - Prev Volume: 0 - Float: 0.7 - Rel Vol: 10240.5x - Chng%: +28.8% $IMG - Volume: 211.6M - Prev Volume: 0 - Float: 5.38 - Rel Vol: 4294.6x - Chng%: +144.9% $DUOL - Volume: 234K - Prev Volume: 0 - Float: 37.51 - Rel Vol: 5.1x - Chng%: +27.1% $NAGE - Volume: 111K - Prev Volume: 0 - Float: 50.79 - Rel Vol: 2.0x - Chng%: +15.7%
0 · Reply
buttons
buttons Aug. 7 at 12:10 PM
$NAGE As of today, Louis Navellier has a 'Top 5 buy' in one of his portfolios. He has a 'buy' limit of 15 with an 'aggressive' label. Will post if he raises the buy limit.
0 · Reply
tymtested
tymtested Aug. 7 at 12:06 PM
$NAGE demand for NR will only increase driving stock price up .
0 · Reply
wycliff
wycliff Aug. 7 at 11:48 AM
$NAGE https://www.nasdaq.com/articles/niagen-bioscience-nage-q2-earnings-and-revenues-surpass-estimates
0 · Reply
MattManzanita
MattManzanita Aug. 7 at 6:15 AM
$NAGE Rob Fried said that pharmaceutical companies in the US want NRT, rather than NRCl. The latter is what is in Tru Niagen, and was used in the No Park trials. This will require an additional "bridge" trial since the FDA will not approve NRT based on NRCl trials. The procedure in a bridge trial is less involved than starting from scratch. He also commented that they might seek accelerated approval of the Phase 3 trial in the EU using NRCl. I am not sure why an accelerated approval process would be useful, since the trial was at Phase 3 using 1000 mg. Maybe he was referring to the dose optimization trial that used 3000 mg of NR at Phase 2 regarding accelerated approval. In the EU there are about 1.2 million people with Parkinson's disease.
1 · Reply